Paul A. VanderLaan
Beth Israel Deaconess Medical Center
PathologyLung cancerAdenocarcinomaCancer researchMedicine
What is this?
Publications 118
#1Mayra A. Medina (BIDMC: Beth Israel Deaconess Medical Center)
#2Allison Onken (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 1
Last. Paul A. VanderLaan (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 22
view all 7 authors...
Subsolid lung nodules are defined as focal lung lesions on computed tomography (CT) smaller than 3 cm with a ground glass component (1,2). This category includes nodules with only ground glass attenuation, called “pure ground glass nodules” or “nonsolid nodules”, and nodules with both a ground glass and a solid component, called “part-solid nodules” (1,2).
#1Lucian R. Chirieac (Brigham and Women's Hospital)H-Index: 55
#2Yin P. Hung (Harvard University)H-Index: 15
Last. Raphael Bueno (Brigham and Women's Hospital)H-Index: 59
view all 8 authors...
1 CitationsSource
Tumor spread through airspaces (STAS) has been identified as a new pattern of invasion in the 2015 WHO classification of lung tumors (1) and is associated with a lower overall survival in resected non-small cell lung cancers (2). As a consequence, sublobar resection may not be the best surgical option for cancers with STAS.
#1Constance de Margerie-Mellon (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 8
#2Ritu R. Gill (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 21
Last. Alexander A. Bankier (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 44
view all 7 authors...
Rationale and Objectives To analyze the performances of diameter-based measurements, either using diameters, or by calculating diameter-based volumes, as compared to volume measurements in assessing growth of pulmonary adenocarcinomas manifesting as subsolid nodules on CT. Materials and Methods In this IRB-approved, retrospective study, 74 pulmonary adenocarcinomas presenting as subsolid nodules and resected in 69 patients (21 men, 48 women, mean age 70 ± 9 years) were included. Three CTs were a...
#1Deepa Rangachari (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Ciric To (Harvard University)H-Index: 2
Last. Daniel B. Costa (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 39
view all 11 authors...
Abstract Introduction Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation EGFR inhibitor are evolving. Whether durable control of subsequently osimertinib-resistant NSCLC with the EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile. Methods We used N-et...
1 CitationsSource
#1Kartik SehgalH-Index: 5
#2Meghan SheaH-Index: 5
Last. Deepa RangachariH-Index: 11
view all 8 authors...
#2Fayez KheirH-Index: 7
Last. Adnan MajidH-Index: 22
view all 6 authors...